OrthoPediatrics spent its last earnings call describing a business at an inflection point, and the market briefly agreed. Shares ran to $26.74 after the report before giving much of that back, and they now sit near $21.95, closer to the bottom of the post-earnings range than the top. That retreat frames the third-quarter report, due after the close on October 27: the company does not need to surprise on the top line so much as prove that the second quarter's record revenue, margin and cash flow were the start of a trend rather than a high-water mark.

Wall Street expects revenue of about $68.5 million, up 11.9% from a year ago, with a loss of $0.25 per share, slightly wider than the $0.24 loss in the same quarter last year. On its face, that is a step down from the record $70.5 million posted last quarter, but it is a step management told everyone to expect. Executives guided the third and fourth quarters a couple million dollars below the second, citing seasonality, the timing of 7D capital sales and a dose of conservatism. Full-year guidance, raised for the second straight quarter to $265 million to $269 million, implies 12% to 14% growth. Consensus of roughly $265.1 million sits right at the bottom of that range, which suggests analysts are giving little credit for the latest raise. That leaves room for an upside surprise if the trends from the spring held.

The most important engine is trauma and deformity, which accelerated to 26% growth last quarter from 14% in the first quarter. Management tied that strength to an early product super cycle, and the third quarter is the first full period with meaningful 3P HIP set deployment, which began in late June. VertiGlide adoption is another test: trained surgeons climbed to 124 from about 80 in a single quarter, and continued gains would indicate that training is translating into procedures. International, up 22% on record European results helped by EU MDR approvals, should show whether that regulatory tailwind is durable. Commentary on the new Osseo distribution deal and the 3P Small Mini beta would add color on the 2027 pipeline.

Scoliosis is the wild card. Reported revenue fell 9% last quarter because the company sold no 7D units and deliberately throttled Brazil set sales to prioritize cash collection, even as underlying implant sales grew in the mid-teens. A rebound in reported scoliosis, or at least continued mid-teens implant growth, would support the claim that the decline was timing rather than demand. Another quarter of weakness without a clear 7D explanation would invite tougher questions.

Profitability is where the bar is genuinely high. Adjusted EBITDA reached a record $6.8 million in the second quarter, bringing the first half to $9 million against a reaffirmed $25 million full-year target. Hitting that goal requires roughly $16 million over the back half, or about $8 million a quarter, above the record just set, on revenue guided lower than last quarter. Gross margin, which expanded to 74%, needs to hold or improve. Management also upgraded its free cash flow outlook to breakeven or better with positive second-half generation, so a cash-positive third quarter would be strong confirmation. Below the line, euro translation swung earnings last quarter, so headline EPS may say less about operations than EBITDA does.

Sentiment has warmed noticeably, rising to about 32.6% bullish from 7% ahead of the last report, while the stock has edged slightly ahead of the S&P 500 since then. It remains above its 200-day average near $19.18. Ultimately, the verdict hinges on whether OrthoPediatrics can keep trauma and deformity growth strong while showing a credible path to its EBITDA and cash targets. Delivering both would validate the inflection narrative; slipping on either would make the guidance raises look premature.